Fine-Tuning Cardiac Insulin-Like Growth Factor 1 Receptor Signaling to Promote Health and Longevity

The insulin-like growth factor 1 (IGF1) pathway is a key regulator of cellular metabolism and aging. Although its inhibition promotes longevity across species, the effect of attenuated IGF1 signaling on cardiac aging remains controversial. We performed a lifelong study to assess cardiac health and l...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Circulation (New York, N.Y.) N.Y.), 2022-06, Vol.145 (25), p.1853-1866
Hauptverfasser: Abdellatif, Mahmoud, Trummer-Herbst, Viktoria, Heberle, Alexander Martin, Humnig, Alina, Pendl, Tobias, Durand, Sylvère, Cerrato, Giulia, Hofer, Sebastian J., Islam, Moydul, Voglhuber, Julia, Ramos Pittol, José Miguel, Kepp, Oliver, Hoefler, Gerald, Schmidt, Albrecht, Rainer, Peter P., Scherr, Daniel, von Lewinski, Dirk, Bisping, Egbert, McMullen, Julie R., Diwan, Abhinav, Eisenberg, Tobias, Madeo, Frank, Thedieck, Kathrin, Kroemer, Guido, Sedej, Simon
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1866
container_issue 25
container_start_page 1853
container_title Circulation (New York, N.Y.)
container_volume 145
creator Abdellatif, Mahmoud
Trummer-Herbst, Viktoria
Heberle, Alexander Martin
Humnig, Alina
Pendl, Tobias
Durand, Sylvère
Cerrato, Giulia
Hofer, Sebastian J.
Islam, Moydul
Voglhuber, Julia
Ramos Pittol, José Miguel
Kepp, Oliver
Hoefler, Gerald
Schmidt, Albrecht
Rainer, Peter P.
Scherr, Daniel
von Lewinski, Dirk
Bisping, Egbert
McMullen, Julie R.
Diwan, Abhinav
Eisenberg, Tobias
Madeo, Frank
Thedieck, Kathrin
Kroemer, Guido
Sedej, Simon
description The insulin-like growth factor 1 (IGF1) pathway is a key regulator of cellular metabolism and aging. Although its inhibition promotes longevity across species, the effect of attenuated IGF1 signaling on cardiac aging remains controversial. We performed a lifelong study to assess cardiac health and lifespan in 2 cardiomyocyte-specific transgenic mouse models with enhanced versus reduced IGF1 receptor (IGF1R) signaling. Male mice with human IGF1R overexpression or dominant negative phosphoinositide 3-kinase mutation were examined at different life stages by echocardiography, invasive hemodynamics, and treadmill coupled to indirect calorimetry. In vitro assays included cardiac histology, mitochondrial respiration, ATP synthesis, autophagic flux, and targeted metabolome profiling, and immunoblots of key IGF1R downstream targets in mouse and human explanted failing and nonfailing hearts, as well. Young mice with increased IGF1R signaling exhibited superior cardiac function that progressively declined with aging in an accelerated fashion compared with wild-type animals, resulting in heart failure and a reduced lifespan. In contrast, mice with low cardiac IGF1R signaling exhibited inferior cardiac function early in life, but superior cardiac performance during aging, and increased maximum lifespan, as well. Mechanistically, the late-life detrimental effects of IGF1R activation correlated with suppressed autophagic flux and impaired oxidative phosphorylation in the heart. Low IGF1R activity consistently improved myocardial bioenergetics and function of the aging heart in an autophagy-dependent manner. In humans, failing hearts, but not those with compensated hypertrophy, displayed exaggerated IGF1R expression and signaling activity. Our findings indicate that the relationship between IGF1R signaling and cardiac health is not linear, but rather biphasic. Hence, pharmacological inhibitors of the IGF1 pathway, albeit unsuitable for young individuals, might be worth considering in older adults.
doi_str_mv 10.1161/CIRCULATIONAHA.122.059863
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9203038</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2670061440</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5026-ecbe975d07bafe26752a928194f4a4d713dabb4ed767c7ce5a3c660c529d68c83</originalsourceid><addsrcrecordid>eNpdkl9v0zAUxSMEYmXwFVB4g4cU27Gd-AUpita1UsTQ6J4tx7ltzVK72EmrfXvcZUyMJ_8751xf_5wknzCaY8zx13p1W9811Xp1871aVnNMyBwxUfL8VTLDjNCMsly8TmYIIZEVOSEXybsQfsUlzwv2NrnIGcccsXKW6IWxkK1Ha-w2rZXvjNLpyoaxNzZrzD2k196dhl26UHpwPsXpLWg4nKc_zdaq_uwbXPrDu70bIF2C6qNa2S5tnN3C0QwP75M3G9UH-PA0XiZ3i6t1vcyam-tVXTWZZojwDHQLomAdKlq1AcILRpQgJRZ0QxXtCpx3qm0pdAUvdKGBqVxzjjQjouOlLvPL5NuUexjbPXQa7OBVLw_e7JV_kE4Z-fLEmp3cuqMUBOUoPwd8mQJ2_9mWVSPPe4gyEUvSI47az0_FvPs9Qhjk3gQNfa8suDHIeP_43JhSFKVikmrvQvCwec7GSJ6BypdAZQQqJ6DR-_Hfnp6dfwlGAZ0EJ9cP4MN9P57Ay90jBxmRx9ZwkRFECOIEoww9foM_B92t_w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2670061440</pqid></control><display><type>article</type><title>Fine-Tuning Cardiac Insulin-Like Growth Factor 1 Receptor Signaling to Promote Health and Longevity</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>Journals@Ovid Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Abdellatif, Mahmoud ; Trummer-Herbst, Viktoria ; Heberle, Alexander Martin ; Humnig, Alina ; Pendl, Tobias ; Durand, Sylvère ; Cerrato, Giulia ; Hofer, Sebastian J. ; Islam, Moydul ; Voglhuber, Julia ; Ramos Pittol, José Miguel ; Kepp, Oliver ; Hoefler, Gerald ; Schmidt, Albrecht ; Rainer, Peter P. ; Scherr, Daniel ; von Lewinski, Dirk ; Bisping, Egbert ; McMullen, Julie R. ; Diwan, Abhinav ; Eisenberg, Tobias ; Madeo, Frank ; Thedieck, Kathrin ; Kroemer, Guido ; Sedej, Simon</creator><creatorcontrib>Abdellatif, Mahmoud ; Trummer-Herbst, Viktoria ; Heberle, Alexander Martin ; Humnig, Alina ; Pendl, Tobias ; Durand, Sylvère ; Cerrato, Giulia ; Hofer, Sebastian J. ; Islam, Moydul ; Voglhuber, Julia ; Ramos Pittol, José Miguel ; Kepp, Oliver ; Hoefler, Gerald ; Schmidt, Albrecht ; Rainer, Peter P. ; Scherr, Daniel ; von Lewinski, Dirk ; Bisping, Egbert ; McMullen, Julie R. ; Diwan, Abhinav ; Eisenberg, Tobias ; Madeo, Frank ; Thedieck, Kathrin ; Kroemer, Guido ; Sedej, Simon</creatorcontrib><description>The insulin-like growth factor 1 (IGF1) pathway is a key regulator of cellular metabolism and aging. Although its inhibition promotes longevity across species, the effect of attenuated IGF1 signaling on cardiac aging remains controversial. We performed a lifelong study to assess cardiac health and lifespan in 2 cardiomyocyte-specific transgenic mouse models with enhanced versus reduced IGF1 receptor (IGF1R) signaling. Male mice with human IGF1R overexpression or dominant negative phosphoinositide 3-kinase mutation were examined at different life stages by echocardiography, invasive hemodynamics, and treadmill coupled to indirect calorimetry. In vitro assays included cardiac histology, mitochondrial respiration, ATP synthesis, autophagic flux, and targeted metabolome profiling, and immunoblots of key IGF1R downstream targets in mouse and human explanted failing and nonfailing hearts, as well. Young mice with increased IGF1R signaling exhibited superior cardiac function that progressively declined with aging in an accelerated fashion compared with wild-type animals, resulting in heart failure and a reduced lifespan. In contrast, mice with low cardiac IGF1R signaling exhibited inferior cardiac function early in life, but superior cardiac performance during aging, and increased maximum lifespan, as well. Mechanistically, the late-life detrimental effects of IGF1R activation correlated with suppressed autophagic flux and impaired oxidative phosphorylation in the heart. Low IGF1R activity consistently improved myocardial bioenergetics and function of the aging heart in an autophagy-dependent manner. In humans, failing hearts, but not those with compensated hypertrophy, displayed exaggerated IGF1R expression and signaling activity. Our findings indicate that the relationship between IGF1R signaling and cardiac health is not linear, but rather biphasic. Hence, pharmacological inhibitors of the IGF1 pathway, albeit unsuitable for young individuals, might be worth considering in older adults.</description><identifier>ISSN: 0009-7322</identifier><identifier>EISSN: 1524-4539</identifier><identifier>DOI: 10.1161/CIRCULATIONAHA.122.059863</identifier><identifier>PMID: 35616058</identifier><language>eng</language><publisher>United States: Lippincott Williams &amp; Wilkins</publisher><subject>Aged ; Animals ; Health Promotion ; Humans ; Insulin-Like Growth Factor I - metabolism ; Life Sciences ; Longevity ; Male ; Mice ; Myocytes, Cardiac - metabolism ; Original s ; Phosphatidylinositol 3-Kinases - metabolism ; Receptor, IGF Type 1 - genetics ; Receptor, IGF Type 1 - metabolism</subject><ispartof>Circulation (New York, N.Y.), 2022-06, Vol.145 (25), p.1853-1866</ispartof><rights>Lippincott Williams &amp; Wilkins</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><rights>2022 The Authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5026-ecbe975d07bafe26752a928194f4a4d713dabb4ed767c7ce5a3c660c529d68c83</citedby><cites>FETCH-LOGICAL-c5026-ecbe975d07bafe26752a928194f4a4d713dabb4ed767c7ce5a3c660c529d68c83</cites><orcidid>0000-0001-6414-8707 ; 0000-0003-4623-0330 ; 0000-0003-0102-7902 ; 0000-0003-2755-2860 ; 0000-0003-3559-1130 ; 0000-0002-3828-9562 ; 0000-0002-4419-6821 ; 0000-0002-5042-9054 ; 0000-0002-2840-6454 ; 0000-0002-9334-4405 ; 0000-0002-6081-9558 ; 0000-0002-0756-0014 ; 0000-0003-3753-5394 ; 0000-0002-9069-2930</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,3687,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35616058$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-04596604$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Abdellatif, Mahmoud</creatorcontrib><creatorcontrib>Trummer-Herbst, Viktoria</creatorcontrib><creatorcontrib>Heberle, Alexander Martin</creatorcontrib><creatorcontrib>Humnig, Alina</creatorcontrib><creatorcontrib>Pendl, Tobias</creatorcontrib><creatorcontrib>Durand, Sylvère</creatorcontrib><creatorcontrib>Cerrato, Giulia</creatorcontrib><creatorcontrib>Hofer, Sebastian J.</creatorcontrib><creatorcontrib>Islam, Moydul</creatorcontrib><creatorcontrib>Voglhuber, Julia</creatorcontrib><creatorcontrib>Ramos Pittol, José Miguel</creatorcontrib><creatorcontrib>Kepp, Oliver</creatorcontrib><creatorcontrib>Hoefler, Gerald</creatorcontrib><creatorcontrib>Schmidt, Albrecht</creatorcontrib><creatorcontrib>Rainer, Peter P.</creatorcontrib><creatorcontrib>Scherr, Daniel</creatorcontrib><creatorcontrib>von Lewinski, Dirk</creatorcontrib><creatorcontrib>Bisping, Egbert</creatorcontrib><creatorcontrib>McMullen, Julie R.</creatorcontrib><creatorcontrib>Diwan, Abhinav</creatorcontrib><creatorcontrib>Eisenberg, Tobias</creatorcontrib><creatorcontrib>Madeo, Frank</creatorcontrib><creatorcontrib>Thedieck, Kathrin</creatorcontrib><creatorcontrib>Kroemer, Guido</creatorcontrib><creatorcontrib>Sedej, Simon</creatorcontrib><title>Fine-Tuning Cardiac Insulin-Like Growth Factor 1 Receptor Signaling to Promote Health and Longevity</title><title>Circulation (New York, N.Y.)</title><addtitle>Circulation</addtitle><description>The insulin-like growth factor 1 (IGF1) pathway is a key regulator of cellular metabolism and aging. Although its inhibition promotes longevity across species, the effect of attenuated IGF1 signaling on cardiac aging remains controversial. We performed a lifelong study to assess cardiac health and lifespan in 2 cardiomyocyte-specific transgenic mouse models with enhanced versus reduced IGF1 receptor (IGF1R) signaling. Male mice with human IGF1R overexpression or dominant negative phosphoinositide 3-kinase mutation were examined at different life stages by echocardiography, invasive hemodynamics, and treadmill coupled to indirect calorimetry. In vitro assays included cardiac histology, mitochondrial respiration, ATP synthesis, autophagic flux, and targeted metabolome profiling, and immunoblots of key IGF1R downstream targets in mouse and human explanted failing and nonfailing hearts, as well. Young mice with increased IGF1R signaling exhibited superior cardiac function that progressively declined with aging in an accelerated fashion compared with wild-type animals, resulting in heart failure and a reduced lifespan. In contrast, mice with low cardiac IGF1R signaling exhibited inferior cardiac function early in life, but superior cardiac performance during aging, and increased maximum lifespan, as well. Mechanistically, the late-life detrimental effects of IGF1R activation correlated with suppressed autophagic flux and impaired oxidative phosphorylation in the heart. Low IGF1R activity consistently improved myocardial bioenergetics and function of the aging heart in an autophagy-dependent manner. In humans, failing hearts, but not those with compensated hypertrophy, displayed exaggerated IGF1R expression and signaling activity. Our findings indicate that the relationship between IGF1R signaling and cardiac health is not linear, but rather biphasic. Hence, pharmacological inhibitors of the IGF1 pathway, albeit unsuitable for young individuals, might be worth considering in older adults.</description><subject>Aged</subject><subject>Animals</subject><subject>Health Promotion</subject><subject>Humans</subject><subject>Insulin-Like Growth Factor I - metabolism</subject><subject>Life Sciences</subject><subject>Longevity</subject><subject>Male</subject><subject>Mice</subject><subject>Myocytes, Cardiac - metabolism</subject><subject>Original s</subject><subject>Phosphatidylinositol 3-Kinases - metabolism</subject><subject>Receptor, IGF Type 1 - genetics</subject><subject>Receptor, IGF Type 1 - metabolism</subject><issn>0009-7322</issn><issn>1524-4539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkl9v0zAUxSMEYmXwFVB4g4cU27Gd-AUpita1UsTQ6J4tx7ltzVK72EmrfXvcZUyMJ_8751xf_5wknzCaY8zx13p1W9811Xp1871aVnNMyBwxUfL8VTLDjNCMsly8TmYIIZEVOSEXybsQfsUlzwv2NrnIGcccsXKW6IWxkK1Ha-w2rZXvjNLpyoaxNzZrzD2k196dhl26UHpwPsXpLWg4nKc_zdaq_uwbXPrDu70bIF2C6qNa2S5tnN3C0QwP75M3G9UH-PA0XiZ3i6t1vcyam-tVXTWZZojwDHQLomAdKlq1AcILRpQgJRZ0QxXtCpx3qm0pdAUvdKGBqVxzjjQjouOlLvPL5NuUexjbPXQa7OBVLw_e7JV_kE4Z-fLEmp3cuqMUBOUoPwd8mQJ2_9mWVSPPe4gyEUvSI47az0_FvPs9Qhjk3gQNfa8suDHIeP_43JhSFKVikmrvQvCwec7GSJ6BypdAZQQqJ6DR-_Hfnp6dfwlGAZ0EJ9cP4MN9P57Ay90jBxmRx9ZwkRFECOIEoww9foM_B92t_w</recordid><startdate>20220621</startdate><enddate>20220621</enddate><creator>Abdellatif, Mahmoud</creator><creator>Trummer-Herbst, Viktoria</creator><creator>Heberle, Alexander Martin</creator><creator>Humnig, Alina</creator><creator>Pendl, Tobias</creator><creator>Durand, Sylvère</creator><creator>Cerrato, Giulia</creator><creator>Hofer, Sebastian J.</creator><creator>Islam, Moydul</creator><creator>Voglhuber, Julia</creator><creator>Ramos Pittol, José Miguel</creator><creator>Kepp, Oliver</creator><creator>Hoefler, Gerald</creator><creator>Schmidt, Albrecht</creator><creator>Rainer, Peter P.</creator><creator>Scherr, Daniel</creator><creator>von Lewinski, Dirk</creator><creator>Bisping, Egbert</creator><creator>McMullen, Julie R.</creator><creator>Diwan, Abhinav</creator><creator>Eisenberg, Tobias</creator><creator>Madeo, Frank</creator><creator>Thedieck, Kathrin</creator><creator>Kroemer, Guido</creator><creator>Sedej, Simon</creator><general>Lippincott Williams &amp; Wilkins</general><general>American Heart Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6414-8707</orcidid><orcidid>https://orcid.org/0000-0003-4623-0330</orcidid><orcidid>https://orcid.org/0000-0003-0102-7902</orcidid><orcidid>https://orcid.org/0000-0003-2755-2860</orcidid><orcidid>https://orcid.org/0000-0003-3559-1130</orcidid><orcidid>https://orcid.org/0000-0002-3828-9562</orcidid><orcidid>https://orcid.org/0000-0002-4419-6821</orcidid><orcidid>https://orcid.org/0000-0002-5042-9054</orcidid><orcidid>https://orcid.org/0000-0002-2840-6454</orcidid><orcidid>https://orcid.org/0000-0002-9334-4405</orcidid><orcidid>https://orcid.org/0000-0002-6081-9558</orcidid><orcidid>https://orcid.org/0000-0002-0756-0014</orcidid><orcidid>https://orcid.org/0000-0003-3753-5394</orcidid><orcidid>https://orcid.org/0000-0002-9069-2930</orcidid></search><sort><creationdate>20220621</creationdate><title>Fine-Tuning Cardiac Insulin-Like Growth Factor 1 Receptor Signaling to Promote Health and Longevity</title><author>Abdellatif, Mahmoud ; Trummer-Herbst, Viktoria ; Heberle, Alexander Martin ; Humnig, Alina ; Pendl, Tobias ; Durand, Sylvère ; Cerrato, Giulia ; Hofer, Sebastian J. ; Islam, Moydul ; Voglhuber, Julia ; Ramos Pittol, José Miguel ; Kepp, Oliver ; Hoefler, Gerald ; Schmidt, Albrecht ; Rainer, Peter P. ; Scherr, Daniel ; von Lewinski, Dirk ; Bisping, Egbert ; McMullen, Julie R. ; Diwan, Abhinav ; Eisenberg, Tobias ; Madeo, Frank ; Thedieck, Kathrin ; Kroemer, Guido ; Sedej, Simon</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5026-ecbe975d07bafe26752a928194f4a4d713dabb4ed767c7ce5a3c660c529d68c83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Aged</topic><topic>Animals</topic><topic>Health Promotion</topic><topic>Humans</topic><topic>Insulin-Like Growth Factor I - metabolism</topic><topic>Life Sciences</topic><topic>Longevity</topic><topic>Male</topic><topic>Mice</topic><topic>Myocytes, Cardiac - metabolism</topic><topic>Original s</topic><topic>Phosphatidylinositol 3-Kinases - metabolism</topic><topic>Receptor, IGF Type 1 - genetics</topic><topic>Receptor, IGF Type 1 - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abdellatif, Mahmoud</creatorcontrib><creatorcontrib>Trummer-Herbst, Viktoria</creatorcontrib><creatorcontrib>Heberle, Alexander Martin</creatorcontrib><creatorcontrib>Humnig, Alina</creatorcontrib><creatorcontrib>Pendl, Tobias</creatorcontrib><creatorcontrib>Durand, Sylvère</creatorcontrib><creatorcontrib>Cerrato, Giulia</creatorcontrib><creatorcontrib>Hofer, Sebastian J.</creatorcontrib><creatorcontrib>Islam, Moydul</creatorcontrib><creatorcontrib>Voglhuber, Julia</creatorcontrib><creatorcontrib>Ramos Pittol, José Miguel</creatorcontrib><creatorcontrib>Kepp, Oliver</creatorcontrib><creatorcontrib>Hoefler, Gerald</creatorcontrib><creatorcontrib>Schmidt, Albrecht</creatorcontrib><creatorcontrib>Rainer, Peter P.</creatorcontrib><creatorcontrib>Scherr, Daniel</creatorcontrib><creatorcontrib>von Lewinski, Dirk</creatorcontrib><creatorcontrib>Bisping, Egbert</creatorcontrib><creatorcontrib>McMullen, Julie R.</creatorcontrib><creatorcontrib>Diwan, Abhinav</creatorcontrib><creatorcontrib>Eisenberg, Tobias</creatorcontrib><creatorcontrib>Madeo, Frank</creatorcontrib><creatorcontrib>Thedieck, Kathrin</creatorcontrib><creatorcontrib>Kroemer, Guido</creatorcontrib><creatorcontrib>Sedej, Simon</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Circulation (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abdellatif, Mahmoud</au><au>Trummer-Herbst, Viktoria</au><au>Heberle, Alexander Martin</au><au>Humnig, Alina</au><au>Pendl, Tobias</au><au>Durand, Sylvère</au><au>Cerrato, Giulia</au><au>Hofer, Sebastian J.</au><au>Islam, Moydul</au><au>Voglhuber, Julia</au><au>Ramos Pittol, José Miguel</au><au>Kepp, Oliver</au><au>Hoefler, Gerald</au><au>Schmidt, Albrecht</au><au>Rainer, Peter P.</au><au>Scherr, Daniel</au><au>von Lewinski, Dirk</au><au>Bisping, Egbert</au><au>McMullen, Julie R.</au><au>Diwan, Abhinav</au><au>Eisenberg, Tobias</au><au>Madeo, Frank</au><au>Thedieck, Kathrin</au><au>Kroemer, Guido</au><au>Sedej, Simon</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fine-Tuning Cardiac Insulin-Like Growth Factor 1 Receptor Signaling to Promote Health and Longevity</atitle><jtitle>Circulation (New York, N.Y.)</jtitle><addtitle>Circulation</addtitle><date>2022-06-21</date><risdate>2022</risdate><volume>145</volume><issue>25</issue><spage>1853</spage><epage>1866</epage><pages>1853-1866</pages><issn>0009-7322</issn><eissn>1524-4539</eissn><abstract>The insulin-like growth factor 1 (IGF1) pathway is a key regulator of cellular metabolism and aging. Although its inhibition promotes longevity across species, the effect of attenuated IGF1 signaling on cardiac aging remains controversial. We performed a lifelong study to assess cardiac health and lifespan in 2 cardiomyocyte-specific transgenic mouse models with enhanced versus reduced IGF1 receptor (IGF1R) signaling. Male mice with human IGF1R overexpression or dominant negative phosphoinositide 3-kinase mutation were examined at different life stages by echocardiography, invasive hemodynamics, and treadmill coupled to indirect calorimetry. In vitro assays included cardiac histology, mitochondrial respiration, ATP synthesis, autophagic flux, and targeted metabolome profiling, and immunoblots of key IGF1R downstream targets in mouse and human explanted failing and nonfailing hearts, as well. Young mice with increased IGF1R signaling exhibited superior cardiac function that progressively declined with aging in an accelerated fashion compared with wild-type animals, resulting in heart failure and a reduced lifespan. In contrast, mice with low cardiac IGF1R signaling exhibited inferior cardiac function early in life, but superior cardiac performance during aging, and increased maximum lifespan, as well. Mechanistically, the late-life detrimental effects of IGF1R activation correlated with suppressed autophagic flux and impaired oxidative phosphorylation in the heart. Low IGF1R activity consistently improved myocardial bioenergetics and function of the aging heart in an autophagy-dependent manner. In humans, failing hearts, but not those with compensated hypertrophy, displayed exaggerated IGF1R expression and signaling activity. Our findings indicate that the relationship between IGF1R signaling and cardiac health is not linear, but rather biphasic. Hence, pharmacological inhibitors of the IGF1 pathway, albeit unsuitable for young individuals, might be worth considering in older adults.</abstract><cop>United States</cop><pub>Lippincott Williams &amp; Wilkins</pub><pmid>35616058</pmid><doi>10.1161/CIRCULATIONAHA.122.059863</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0001-6414-8707</orcidid><orcidid>https://orcid.org/0000-0003-4623-0330</orcidid><orcidid>https://orcid.org/0000-0003-0102-7902</orcidid><orcidid>https://orcid.org/0000-0003-2755-2860</orcidid><orcidid>https://orcid.org/0000-0003-3559-1130</orcidid><orcidid>https://orcid.org/0000-0002-3828-9562</orcidid><orcidid>https://orcid.org/0000-0002-4419-6821</orcidid><orcidid>https://orcid.org/0000-0002-5042-9054</orcidid><orcidid>https://orcid.org/0000-0002-2840-6454</orcidid><orcidid>https://orcid.org/0000-0002-9334-4405</orcidid><orcidid>https://orcid.org/0000-0002-6081-9558</orcidid><orcidid>https://orcid.org/0000-0002-0756-0014</orcidid><orcidid>https://orcid.org/0000-0003-3753-5394</orcidid><orcidid>https://orcid.org/0000-0002-9069-2930</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0009-7322
ispartof Circulation (New York, N.Y.), 2022-06, Vol.145 (25), p.1853-1866
issn 0009-7322
1524-4539
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9203038
source MEDLINE; American Heart Association Journals; Journals@Ovid Complete; EZB-FREE-00999 freely available EZB journals
subjects Aged
Animals
Health Promotion
Humans
Insulin-Like Growth Factor I - metabolism
Life Sciences
Longevity
Male
Mice
Myocytes, Cardiac - metabolism
Original s
Phosphatidylinositol 3-Kinases - metabolism
Receptor, IGF Type 1 - genetics
Receptor, IGF Type 1 - metabolism
title Fine-Tuning Cardiac Insulin-Like Growth Factor 1 Receptor Signaling to Promote Health and Longevity
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T20%3A30%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fine-Tuning%20Cardiac%20Insulin-Like%20Growth%20Factor%201%20Receptor%20Signaling%20to%20Promote%20Health%20and%20Longevity&rft.jtitle=Circulation%20(New%20York,%20N.Y.)&rft.au=Abdellatif,%20Mahmoud&rft.date=2022-06-21&rft.volume=145&rft.issue=25&rft.spage=1853&rft.epage=1866&rft.pages=1853-1866&rft.issn=0009-7322&rft.eissn=1524-4539&rft_id=info:doi/10.1161/CIRCULATIONAHA.122.059863&rft_dat=%3Cproquest_pubme%3E2670061440%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2670061440&rft_id=info:pmid/35616058&rfr_iscdi=true